Leap Therapeutics, Inc.

Leap Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of innovative cancer therapies. Its primary focus is on creating monoclonal antibody treatments designed to exploit the body's immune system to target and eliminate cancer cells. A significant aspect of its mission is researching therapies that treat difficult-to-treat cancers, particularly those with limited treatment options. The company's lead candidate involves the treatment of cancers expressing the mesothelin protein, which is prevalent in several hard-to-treat cancers such as mesothelioma, ovarian cancer, and pancreatic cancer. The biopharmaceutical sector is a rapidly evolving field where Leap Therapeutics plays a critical role by advancing the next generation of cancer treatments. With its focus on innovative immunotherapy, Leap Therapeutics is at the forefront of personalized medicine, aiming to provide more effective and less invasive cancer treatments. Founded to translate complex scientific discoveries into meaningful clinical outcomes, the company significantly contributes to the biotechnology industry and the broader healthcare market.